KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Depreciation and Depletion (2021 - 2025)

Emergent BioSolutions' Depreciation and Depletion history spans 5 years, with the latest figure at $7.2 million for Q4 2025.

  • For Q4 2025, Depreciation and Depletion fell 25.77% year-over-year to $7.2 million; the TTM value through Dec 2025 reached $30.7 million, down 29.75%, while the annual FY2025 figure was $30.7 million, 29.75% down from the prior year.
  • Depreciation and Depletion reached $7.2 million in Q4 2025 per EBS's latest filing, up from $7.1 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $28.5 million in Q2 2022 to a low of $7.1 million in Q3 2025.
  • Average Depreciation and Depletion over 5 years is $14.0 million, with a median of $13.5 million recorded in 2021.
  • Peak YoY movement for Depreciation and Depletion: skyrocketed 54.05% in 2022, then plummeted 42.36% in 2023.
  • A 5-year view of Depreciation and Depletion shows it stood at $15.7 million in 2021, then grew by 14.65% to $18.0 million in 2022, then decreased by 25.56% to $13.4 million in 2023, then dropped by 27.61% to $9.7 million in 2024, then dropped by 25.77% to $7.2 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Depreciation and Depletion are $7.2 million (Q4 2025), $7.1 million (Q3 2025), and $7.3 million (Q2 2025).